Three Undiscovered Gems In India To Enhance Your Portfolio
In This Article:
In the last week, the Indian market has stayed flat, yet it is up 44% over the past year with earnings expected to grow by 17% per annum over the next few years. In such a dynamic environment, identifying stocks with strong growth potential and solid fundamentals can be key to enhancing your portfolio.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Shree Digvijay Cement | 0.01% | 13.97% | 16.37% | ★★★★★★ |
| Vidhi Specialty Food Ingredients | 7.27% | 11.00% | 4.02% | ★★★★★★ |
| Aeroflex Industries | 0.04% | 14.69% | 33.38% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 46.55% | 46.96% | ★★★★★★ |
| Bengal & Assam | 4.48% | 1.54% | 51.11% | ★★★★★☆ |
| Voith Paper Fabrics India | 0.07% | 10.95% | 9.70% | ★★★★★☆ |
| Gallantt Ispat | 18.85% | 37.56% | 37.26% | ★★★★★☆ |
| Piccadily Agro Industries | 50.57% | 13.86% | 42.85% | ★★★★★☆ |
| Insolation Energy | 88.64% | 163.87% | 419.31% | ★★★★★☆ |
| Sanstar | 50.30% | -8.41% | 48.59% | ★★★★☆☆ |
We're going to check out a few of the best picks from our screener tool.
IIFL Securities
Simply Wall St Value Rating: ★★★★☆☆
Overview: IIFL Securities Limited offers capital market services in India's primary and secondary markets, with a market cap of ?68.43 billion.
Operations: IIFL Securities Limited generates revenue primarily from capital market activities (?20.25 billion), with additional income from facilities and ancillary services (?375.25 million) and insurance broking and ancillary services (?2.77 billion).
IIFL Securities, a notable player in India's financial sector, has shown impressive earnings growth of 120.4% over the past year, outpacing the industry average of 64%. The company's price-to-earnings ratio stands at an attractive 12.4x compared to the Indian market's 32.9x. Despite recent volatility in share price and a penalty from SEBI for technical errors, IIFLSEC's net debt to equity ratio is satisfactory at 35.5%, and its high-quality earnings underscore its potential as an investment gem.
-
Get an in-depth perspective on IIFL Securities' performance by reading our health report here.
-
Evaluate IIFL Securities' historical performance by accessing our past performance report.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ?99.76 billion.
Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical segment, which amounted to ?22.68 billion. The company has a market cap of ?99.76 billion.